CDTX - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Cidara Therapeutics

Cidara Therapeutics (CDTX) profitability is supported by the success of Rezzayo and its alliance with Janssen. The quarterly EPS trend reflects current volatility, with the metric standing at -26.70. The company develops advanced immunotherapies to combat infections. However, the loss of a key counterparty and strict FDA oversight create risks for ecosystem development, necessitating the urgent procurement of new investment agreements.

This indicator assesses the efficiency of net income generation per share on a quarterly basis. This quarterly EPS chart visualizes the rate of change in the company's equity. The metric is calculated by comparing the bottom-line financial result with the number of shares outstanding. For Cidara Therapeutics (CDTX), this figure reflects the resource burn rate. The absence of revenue makes profit dynamics dependent on one-time partner tranches.